

Product Data Sheet

Product Name: JQKD82 (hydrochloride)

Cat. No.: GC92037

Chemical Properties

Cas. No. 2863676-87-1

Chemical Name 2-[[[2-[[2-(dimethylamino)ethyl]ethylamino]-2-oxoethyl]amino]methyl]-4-pyridinecarboxylic acid, 2,4-bis(1-methylethoxy)phenyl ester, trihydrochloride

SMILES O=C(C1=CC(CNCC(N(CCN(C)C)CC)=O)=NC=C1)OC2=CC=C(OC(C)C)C=C2OC(C)C.Cl.Cl.Cl

Formula $C_{27}H_{40}N_4O_5 \cdot 3HCl$

M.Wt 610


Solubility DMSO: Sparingly soluble: 1-10 mg/ml, PBS (pH 7.2): Soluble: ≥ 10 mg/ml

Storage $-20^{\circ}C$

General tips For obtaining a higher solubility, please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

JQKD82 is a prodrug form of KDM5-C49, an inhibitor of Jumonji AT-rich interactive domain 1A (JARID1A), also known as lysine-specific demethylase 5A (KDM5A).¹ It increases the levels of trimethylated lysine 4 on histone 3 (H3K4me3) in MOLP-8 and MM.1S multiple myeloma cells when used at concentrations of 0.3 and 1 μ M. JQKD82 reduces the proliferation of MOLP-8 and MM.1S cells in a concentration-dependent manner and decreases the viability of primary CD138⁺ cells from patients with multiple myeloma when used at a concentration of 3 μ M. It induces cell cycle arrest at

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

the G₀/G₁ phase, as well as induces apoptosis, in MOLP-8 and MM.1S cells when used at a concentration of 1 μ M. JQKD82 (50 mg/kg twice per day) decreases tumor growth and increases survival in a MOLP-8 mouse xenograft model.

References:

[1]. Ohguchi, H., Park, P.M.C., Wang, T., et al. Lysine demethylase 5A is required for MYC-driven transcription in multiple myeloma. *Blood Cancer Discov.* 2(4):370-387(2021).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA